International Clinical Trial: Phase I Clinical Trial of Intrathecal Injection of PD-1/VEGF Antibody for Leptomeningeal Metastases from Non-Small Cell Lung Cancer and Biomarker Exploration

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115215) titled 'Phase I Clinical Trial of Intrathecal Injection of PD-1/VEGF Antibody for Leptomeningeal Metastases from Non-Small Cell Lung Cancer and Biomarker Exploration' on Dec. 23, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Hangzhou Cancer Hospital

Condition: Leptomeningeal Metastases from Non-Small Cell Lung Cancer

Intervention: Experimental group (Dose escalation stage):Using a "3+3" design, evaluate the efficacy of IT Ivoxidan at three dose levels (25mg, 50mg, 100mg).

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2026-01-01

Target Sample Size: E...